Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials.

Mayer, Katharina A; Budde, Klemens; Jilma, Bernd; Doberer, Konstantin; Böhmig, Georg A

Mayer, Katharina A; Budde, Klemens; Jilma, Bernd; Doberer, Konstantin; Böhmig, Georg A.

Afiliación

Mayer KA; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Budde K; Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Doberer K; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Böhmig GA; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Expert Opin Emerg Drugs ; 27(2): 151-167, 2022 06.

Article en En | MEDLINE | ID: mdl-35715978

Asunto(s)

Rechazo de Injerto; Trasplante de Riñón; Bortezomib/uso terapéutico; Ensayos Clínicos Fase II como Asunto; Ensayos Clínicos Fase III como Asunto; Rechazo de Injerto/tratamiento farmacológico; Supervivencia de Injerto; Humanos; Isoanticuerpos; Trasplante de Riñón/efectos adversos

Palabras clave

Antibody-mediated rejection; apheresis; bortezomib; clazakizumab; complement blockade; felzartamab; imlifidase; plasmapheresis; tocilizumab; transplantation

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Riñón / Rechazo de Injerto Límite: Humans Idioma: En Revista: Expert Opin Emerg Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Austria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google